Targeting inflammation for depression treatment
Treatments studied
Part of Mental health clinical trials.
This trial tests whether a medication that targets inflammation in the body can help relieve depression symptoms. You will have blood tests and an MRI to see how your brain and immune system respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 25 and 55 years old.
- You need a diagnosis of major depression or bipolar depression.
- You must be off all psychiatric medications for at least 4 weeks before starting (8 weeks if you were on fluoxetine/Prozac).
- You must have a blood test showing higher levels of inflammation (CRP of 3 or higher).
- You cannot have an autoimmune disease, hepatitis B or C, HIV, or a history of cancer (except minor skin cancer).
- You cannot have unstable heart, kidney, liver, or blood conditions, or a recent infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.
This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.
This trial tests whether anti-inflammatory drugs can help reduce symptoms of depression. If you are currently having a major depressive episode and have tried other treatments, this study may offer a new option.
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
This early-stage study tests how your brain responds to an “inflammatory challenge” in people with major depressive disorder and in healthy volunteers. It may help researchers understand the immune-to-brain link in depression and guide future treatments.
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.